Description

Semaglutide represents a sophisticated synthetic analogue of glucagon-like peptide-1, engineered to provide enhanced stability and extended duration of action for research applications. The compound exhibits the molecular formula C187H291N45O59 with a molecular weight of 4114 g/mol and demonstrates 94% sequence homology with endogenous human GLP-1. The structural modifications include strategic amino acid substitutions at positions 8 and 34, where Œ±-aminoisobutyric acid (Aib) replaces alanine at position 8 and arginine substitutes for lysine at position 34. Additionally, the peptide features acylation at lysine-26 with a C18 fatty acid chain, which significantly extends the compound’s half-life through albumin binding. Semaglutide functions as a selective GLP-1 receptor agonist, demonstrating high binding affinity and activation of GLP-1 receptors in laboratory systems. For research use only.